<DOC>
	<DOC>NCT02306811</DOC>
	<brief_summary>Primary Objective: To assess the long-term safety of vatelizumab in MS patients Secondary Objective: To assess the long-term efficacy of vatelizumab</brief_summary>
	<brief_title>Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839</brief_title>
	<detailed_description>The maximum study duration per patient will be 192 weeks, including a Treatment Period of 96 weeks and Post-treatment Safety Follow-up Period of 96 weeks.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Inclusion criteria: Patients who completed the 12week treatment period in DRI13839. Exclusion criteria: Any clinically significant or ongoing adverse events, or laboratory abnormalities from DRI13839 that per Investigator judgment would adversely affect the patient's participation in the longterm extension study. Confirmed platelet count below the lower limit of normal at any time during DRI13839. Pregnancy or breastfeeding. Other protocol defined exclusion criteria may apply. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>